FDA Gives Nod To TScan Therapeutics' Early-Stage Trial Of TSC-100 In Hematologic Malignancies

The FDA has signed off TScan Therapeutics Inc's (NASDAQ: TCRX) investigational new drug (IND) application for TSC-100 in hematologic malignancies patients undergoing allogeneic hematopoietic cell transplantation (HCT).

• The target of TSC-100 is the minor histocompatibility antigen HA-1, which is a lineage-specific antigen found on blood cells.

• The Company will now submit the clinical protocol to Institutional Review Boards (IRB) for the initial study sites and expects to begin dosing patients in 1H of 2022.

• Preliminary data is expected in 2H of 2022.

• TScan plans to initiate a multi-arm Phase 1 umbrella trial designed to evaluate TSC-100 compared to standard-of-care in patients undergoing allogeneic HCT.

• The Company will then initiate the TSC-101 arm of this trial in the same patient population. Primary endpoints include safety and dose-finding.

• As of September 30, 2021, the Company held cash & cash equivalents of 2.9 million that is expected to fund its operating expenses into 2024.

• Price Action: TCRX shares are trading 6.05% lower at $4.33 during the market session on the last check Monday.

See more from Benzinga

• On Positive Virology Data, SAB Biotherapeutics' COVID-19 Drug To Move To Phase 3 In NIH ACTIV-2 Trial

• Ionis' Eplontersen Receives FDA Orphan Drug Status For Misfolded Protein Disorder

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.